David Panossian, MD
Sleep Medicine · Klamath Falls, ORNPI 1366504532
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $618 of the $822 with a category attached, or 75.1%. It is spread thinly across 10 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations.
Across 24 payments — averaging $34.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$189
- Boehringer Ingelheim$173
- Sanofi-aventis U.S. LLC$172
- Jazz Pharmaceuticals Inc.$138
- United Therapeutics Corporation$34
- Insmed, Inc.$32
- plus $83 from 4 others
What the payments were for
- Food & beverage$61875%
- Education$20425%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 8 | $189 |
| Boehringer Ingelheim | 4 | $173 |
| Sanofi-aventis U.S. LLC | 2 | $172 |
| Jazz Pharmaceuticals Inc. | 1 | $138 |
| United Therapeutics Corporation | 2 | $34 |
| Insmed, Inc. | 2 | $32 |
| Genentech USA, Inc. | 2 | $30 |
| Gilead | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XYWAV$138
How this compares
$822 in reported general payments places this provider in the 75th percentile of 36 sleep medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 31 | $386,168 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 198 | $231,733 |
| XolairOmalizumab | 27 | $220,684 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 30 | $193,515 |
| EsbrietPirfenidone | 16 | $130,684 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 118 | $99,812 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 87 | $71,594 |
| Pirfenidone | 62 | $70,837 |
| Fasenra PenBenralizumab | 11 | $56,103 |
| Breo ElliptaFluticasone/Vilanterol | 62 | $40,376 |
| Spiriva RespimatTiotropium Bromide | 31 | $40,159 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 87 | $16,939 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 29 | $16,795 |
| Advair HfaFluticasone Propion/Salmeterol | 21 | $13,238 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $11,477 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $173 | $497,921149 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $189 | $383,399393 claims |
| Genentech USA, Inc.Esbriet | $30 | $130,68416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 36 sleep medicine providers in Oregon.
Other sleep medicine in Klamath Falls
- Radhika BreadenPortland$55K
- Anas RihawiPortland$5K
- Asha SinghBend$4K
- Jennifer KimPortland$2K
- Natalia UsatiiBend$1K
- David ShahaEugene$1K
- Daniel RootPortland$1K
- Bradley DekorteMedford$1K
- Jonathan BrewerBend$757
- Vivek DograPortland$729
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.